These findings strongly support our hypothesis that the therapeutic targeting of GSK-3β with the novel inhibitor, 9-ING-41, reduces myofibroblast differentiation, collagen deposition, and subsequent PF in vivo. This evidence concerns the gene GSK3B and pemphigus foliaceus.